Spatial Regulation of T-Cell Signaling by Programmed Death-Ligand 1 on Wireframe DNA Origami Flat Sheets

Trixy Fang1, Jonatan Alvelid2, Joel Spratt1

  • 1Department of Medical Biochemistry and Biophysics, Karolinska Institute, 171 65 Stockholm, Sweden.

ACS Nano
|February 8, 2021
PubMed

Insights

The spatial arrangement of PD-L1 ligands on DNA origami sheets dictates their impact on T-cell signaling. Specifically, a 200 nm separation of PD-L1 inhibited T-cell activation, suggesting a role for ligand spacing in immunomodulation.

Area of Science:

  • Immunology
  • Nanotechnology
  • Cell Biology

Background:

  • Programmed Death-1 (PD-1) is a receptor on T cells that suppresses immune responses.
  • Its ligand, PD-L1, binding to PD-1 causes receptor reorganization into microclusters.
  • The precise role of PD-L1 spatial organization in PD-1 clustering and T-cell signaling remains unclear.

Purpose of the Study:

  • To investigate how the nanoscale spatial organization of PD-L1 affects T-cell activation and signaling.
  • To explore the potential of DNA origami nanostructures for precise control of immune cell interactions.

Main Methods:

  • Utilized DNA origami flat sheets to display PD-L1 ligands at controlled nanoscale distances (13 nm, 40 nm, 200 nm).
  • Co-cultured these nanostructures with T cells activated by anti-CD3 and anti-CD28 antibodies.
  • Assessed T-cell signaling inhibition, PD-1 nanoclustering, and Interleukin-2 (IL-2) expression.

Main Results:

  • T-cell activation was induced by DNA origami sheets with CD3/CD28 antibodies.
  • PD-L1 ligands spaced at ~200 nm (FS-PD-L1-200), but not at 13 nm or 40 nm, inhibited T-cell signaling.
  • Inhibition increased with higher ratios of FS-PD-L1-200 to activating antibodies.
  • FS-PD-L1-200 induced smaller PD-1 nanoclusters and greater IL-2 reduction compared to FS-PD-L1-13.

Conclusions:

  • The spatial organization of PD-L1 is a critical determinant of its immunomodulatory function.
  • Nanoscale spacing of PD-L1 influences PD-1 clustering and downstream T-cell signaling.
  • Findings provide a basis for developing nanomedicine-based immunomodulatory therapies targeting T-cell activation.